Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients
Authors' conclusion
This cohort study suggests that SGLT-2i may reduce the risk of liver cirrhosis, decompensated cirrhosis, liver failure, and liver-related and all-cause mortality in T2D patients.
Study context
- Population
- T2D patients, Taiwan National Health Insurance Research Database (2009–2020), excluding viral hepatitis or alcohol-related disordersbefore matching
- Participants
- 282,161 patients
- Exposure
- SGLT2i users vs nonusers
- Outcome
- Liver-related outcomes and all-cause mortality
- Follow-up
- Mean 2.7 years
Methodological detailspropensity-score matched, population-based database
- Propensity-score matched
- Population-based database
Main finding
As reported in the abstract
mean follow-up 2.7 years
Each group vs nonusersEstimate (95 % CI)
SGLT2i
aHR (liver cirrhosis) 0.78(0.70–0.87)
SGLT2i
aHR (decompensated cirrhosis) 0.79(0.70–0.89)
SGLT2i
aHR (liver failure) 0.78(0.68–0.89)
SGLT2i
aHR (all-cause mortality) 0.52(0.51–0.54)
Observational data: associations, not effects.
Further findings
Cirrhosis, liver failure and all-cause mortality vs individual drug classes
- Lower risk with SGLT2i vs DPP-4i, GLP-1 RA, pioglitazone and sulfonylureas
Liver-related mortality
- Lower with SGLT2i than DPP-4i or GLP-1 RA
Original publication
Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients. Diabetes Res Clin Pract. Published 12 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →